Mariano Provencio

Dr. Mariano Provencio

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in The Lancet Oncology
Verified
Journal Article
Closed access
Rafael RosellRafael Rosell
Rafael Rosell
ECEnric Carcereny
Enric Carcereny
RGRadj Gervais
Radj Gervais
AVAlain Vergnenegre
Alain Vergnenegre
BMBartomeu Massuti
Bartomeu Massuti
LPLuis Paz-Ares
Luis Paz-Ares

3 September 2009 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
RRRafael Rosell
Rafael Rosell
TMTeresa Moran
Teresa Moran
CQCristina Queralt
Cristina Queralt
RPRut Porta
Rut Porta
FCFelipe Cardenal
Felipe Cardenal
MTMiquel Taron
Miquel Taron
Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non–small-cell lung cancer. We evaluated the feasibility of large-scale screening for EGFR mutations in such patients and analyzed the association between the mutations and the outcome of erlotinib treatment.

1 November 2020 in The Lancet Oncology
Verified
Journal Article
Closed access
Mariano ProvencioMariano Provencio
Mariano Provencio
ENErnest Nadal
Ernest Nadal
AIAmelia Insa
Amelia Insa
MGMaría Rosario García-Campelo
María Rosario García-Campelo
JCJoaquín Casal-Rubio
Joaquín Casal-Rubio
ACAlberto Cruz-Bermúdez
Alberto Cruz-Bermúdez

16 May 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
Mariano ProvencioMariano Provencio
Mariano Provencio
RSRoberto Serna-Blasco
Roberto Serna-Blasco
Ernest NadalErnest Nadal
Ernest Nadal
AIAmelia Insa
Amelia Insa
MGM. Rosario García-Campelo
M. Rosario García-Campelo
ARAtocha Romero
Atocha Romero
PURPOSE: Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in resectable non–small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials.gov identifier: NCT03081689 ). The 3-year overall survival (OS) and circulating tumor DNA (ctDNA) analysis have not been reported. METHODS: This was an open-label, multicenter, single-arm, phase II trial in which patients with stage IIIA NSCLC, who were deemed to be surgically resectable, were treated with neoadjuvant paclitaxel (200 mg/m2 once a day) and carboplatin (area under curve 6) plus nivolumab (360 mg) once on day 1 of each 21-day cycle, for three cycles, followed by adjuvant nivolumab monotherapy for 1 year (240 mg once every 2 weeks for 4 months, followed by 480 mg once every 4 weeks for 8 months). The 3-year OS and ctDNA analysis were secondary objectives of the trial. RESULTS: OS at 36 months was 81.9% (95% CI, 66.8 to 90.6) in the intention-to-treat population, rising to 91.0% (95% CI, 74.2 to 97.0) in the per-protocol population. Neither tumor mutation burden nor programmed cell death ligand-1 staining was predictive of survival. Conversely, low pretreatment levels of ctDNA were significantly associated with improved progression-free survival and OS (hazard ratio [HR], 0.20; 95% CI, 0.06 to 0.63, and HR, 0.07; 95% CI, 0.01 to 0.39, respectively). Clinical responses according to RECIST v1.1 criteria did not predict survival outcomes. However, undetectable ctDNA levels after neoadjuvant treatment were significantly associated with progression-free survival and OS (HR, 0.26; 95% CI, 0.07 to 0.93, and HR, 0.04; 95% CI, 0.00 to 0.55, respectively). The C-index to predict OS for ctDNA levels after neoadjuvant treatment (0.82) was superior to that of RECIST criteria (0.72). CONCLUSION: The efficacy of neoadjuvant chemotherapy plus nivolumab in resectable NSCLC is supported by 3-year OS. ctDNA levels were significantly associated with OS and outperformed radiologic assessments in the prediction of survival.

1 July 2007 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MCManuel Cobo
Manuel Cobo
DIDolores Isla
Dolores Isla
BMBartomeu Massuti
Bartomeu Massuti
AMAna Montes
Ana Montes
JSJose Miguel Sanchez
Jose Miguel Sanchez
RRRafael Rosell
Rafael Rosell
Purpose: Although current treatment options for metastatic non–small-cell lung cancer (NSCLC) rely on cisplatin-based chemotherapy, individualized approaches to therapy may improve response or reduce unnecessary toxicity. Excision repair cross-complementing 1 (ERCC1) has been associated with cisplatin resistance. We hypothesized that assigning cisplatin based on pretreatment ERCC1 mRNA levels would improve response. Patients and Methods: From August 2001 to October 2005, 444 stage IV NSCLC patients were enrolled. RNA was isolated from pretreatment biopsies, and quantitative real-time reverse transcriptase PCR assays were performed to determine ERCC1 mRNA expression. Patients were randomly assigned in a 1:2 ratio to either the control or genotypic arm before ERCC1 assessment. Patients in the control arm received docetaxel plus cisplatin. In the genotypic arm, patients with low ERCC1 levels received docetaxel plus cisplatin, and those with high levels received docetaxel plus gemcitabine. The primary end point was the overall objective response rate. Results: Of 444 patients enrolled, 78 (17.6%) went off study before receiving one cycle of chemotherapy, mainly due to insufficient tumor tissue for ERCC1 mRNA assessment. Of the remaining 346 patients assessable for response, objective response was attained by 53 patients (39.3%) in the control arm and 107 patients (50.7%) in the genotypic arm (P = .02). Conclusion: Assessment of ERCC1 mRNA expression in patient tumor tissue is feasible in the clinical setting and predicts response to docetaxel and cisplatin. Additional studies are warranted to optimize methodologies for ERCC1 analysis in small tumor samples and to refine a multibiomarker profile predictive of patient outcome.

1 January 2003 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Emanuele ZuccaEmanuele Zucca
Emanuele Zucca
ACA. Conconi
A. Conconi
TMT.I. Mughal
T.I. Mughal
ASA.H. Sarris
A.H. Sarris
JSJ.F. Seymour
J.F. Seymour
MGM.K. Gospodarowicz
M.K. Gospodarowicz
Purpose: To determine clinical features and patterns of outcome of primary testicular diffuse large B-cell lymphomas (DLCL). Patients and Methods: A retrospective international survey of 373 patients with primary testicular DLCL. Results: Most patients presented with localized disease (stage I to II), and the median age at diagnosis was 66 years (range, 19 to 91 years). Anthracycline-based chemotherapy was administered to 255 patients (68%), and prophylactic intrathecal chemotherapy was given to 68 patients (18%); 133 patients (36%) received prophylactic scrotal radiotherapy. Median overall survival was 4.8 years, and median progression-free survival was 4 years. The survival curves showed no clear evidence of a substantial proportion of cured patients. A favorable international prognostic index score (IPI), no B-symptoms, the use of anthracyclines, and prophylactic scrotal radiotherapy were significantly associated with longer survival at multivariate analysis. However, even for patients with stage I disease and good-risk IPI, the outcome seems worse than what was reported for DLCL at other sites. At a median follow-up of 7.6 years, 195 patients (52%) had relapsed. Extranodal recurrence was reported in 140 cases. Relapses in CNS were detected in 56 patients (15%) up to 10 years after presentation. A continuous risk of recurrence in the contralateral testis was seen in patients not receiving scrotal radiotherapy. Conclusion: Testicular DLCL is characterized by a particularly high risk of extranodal relapse even in cases with localized disease at diagnosis. Anthracycline-based chemotherapy, CNS prophylaxis, and contralateral testicular irradiation seem to improve the outcome. Their efficacy is under evaluation in a prospective clinical trial.